There is no accurate clinical data on the mortality rate of uterine cancer, but the mortality rate of early-stage patients is low after active treatment, and the 5-year survival rate can reach about 80%. Uterine cancer is one of the common malignant tumors of female reproductive system, the cause of which is still unclear, and it is considered to be related to the high level of estrogen in the patient’s body and the influence of intrauterine tissues biochemistry and other factors. At present, there is no accurate clinical data on the mortality rate of uterine cancer, but this disease is classified into endometrial cancer and uterine sarcoma according to its type, and most of the patients with early endometrial cancer can have a good effect after active treatment, with a 5-year survival rate of about 80% and a relatively low mortality rate. Meanwhile, according to the severity of endometrial cancer, it is classified as stage I-IV. Among them, stage I uterine cancer refers to the malignant tumor of the patient is only confined to the uterus, and after radical surgery such as total hysterectomy, the 5-year survival rate of the patient can reach about 96%. However, advanced endometrial cancer has relatively higher malignant degree and the possibility of hematogenous metastasis, so the prognosis after treatment is poor and has high possibility of recurrence, and the 5-year survival rate of patients is only 20%~30%, and the mortality rate is relatively high. Although the mortality rate of uterine cancer is not certain, it is recommended that patients should seek medical treatment as early as possible to control the development of the disease and improve the quality of life, so as to avoid delaying the disease.